Hikma Pharmaceuticals Plc logo

Hikma Pharmaceuticals Plc(OTC) HKMPY

Market Cap$4.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+147%
5 Year-19%
1 Year-3%
1 Month+8%
$44.41
+0.02%
+0.01Today
Hikma Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeUSD 44.412026-10-16
Hikma Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.18%USD 42.632026-10-09
1 month+7.5%USD 41.312026-09-16
3 month+7.55%USD 41.292026-07-16
Year to date+10.84%USD 40.072025-12-31
1 year-2.93%USD 45.752025-10-16
3 year-5.31%USD 46.902023-10-17
5 year-18.71%USD 54.632021-10-15
Since inception+147.23%USD 17.962011-03-28

Hikma Pharmaceuticals Plc Financials at a Glance

Market Cap

$4.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$6.63B

Net Income (TTM)

$756.00M

EPS (TTM)

$3.52

P/E Ratio

12.37

Dividend

$1.72

Beta (Volatility)

0.37 (Low)

Price

$44.41

Volume

1,096

Open

$44.41

Previous Close

$44.41

Daily Range

$44.41 - $44.41

52-Week Range

$31.80 - $49.31

Estimated Earnings Date

Feb 24, 2026

HKMPY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals PLC is a global pharmaceutical company specializing in the development, production, and distribution of a diverse range of generic, branded, and in-licensed medicines. The company operates through three main divisions: Injectables, Generics, and Branded products, serving various therapeutic areas across multiple international markets.

Products and Services
  • Injectable medications primarily for hospital use
  • Oral and non-injectable generic formulations for retail
  • Branded generic drugs and licensed products for consumers and hospitals
Growth Outlook
  • Revenue increased to $1.73 billion in Q2 2026, reflecting strong demand
  • Operating income rose to $360 million, showcasing operational efficiency
  • Net income reached $223 million, indicating robust profitability
Financial Highlights
  • Trailing twelve months (TTM) revenue of $6.73 billion, up from previous periods
  • Net profit margin of 11.3%, demonstrating effective cost management
  • Dividend yield of 3.86%, appealing for income-focused investors
Hikma Pharmaceuticals PLC has established a strong presence in the pharmaceutical industry, with a focus on delivering high-quality medications across various therapeutic areas. The company's recent financial performance indicates a positive trajectory, with significant revenue growth and improved profitability metrics. The diverse product portfolio and strategic market positioning enhance its potential for sustained growth. Investors may find Hikma's commitment to innovation and operational efficiency appealing as it navigates the evolving healthcare landscape.
AI Generated • Oct 15, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,400

CEO

Riad Mishlawi

Website

www.hikma.com

Headquarters

London, GL W1H 6AZ, GB

HKMPY Financials

Key Financial Metrics (TTM)

Gross Margin

40.88%

Operating Margin

19.41%

Net Income Margin

11.31%

Return on Equity

15.05%

Return on Capital

13.57%

Return on Assets

6.59%

Earnings Yield

8.08%

Dividend Yield

3.87%

Payout Ratio

46.65%

Stock Overview

Market Cap

$4.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

103.48M

Volume

1.10K

Avg. Volume

437.846

Financials (TTM)

Gross Profit

$2.73B

Operating Income

$1.16B

EBITDA

$1.68B

Operating Cash Flow

$878.62M

Capital Expenditure

-$411.99M

Free Cash Flow

$466.63M

Cash & ST Invst.

$289.00M

Total Debt

$1.96B

Hikma Pharmaceuticals Plc Performance Analysis

Hikma Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,515,446,660-1.5%
20232023-12-31USD 2,886,143,70614.7%
20242024-12-31USD 3,128,315,8068.4%
20252025-12-31USD 3,356,826,1807.3%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-0.7%
Q22025-06-306.4%
Q42025-12-311.6%
Q22026-06-302.6%
Hikma Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 1.67-53.8%
20232023-12-31USD 1.722.7%
20242024-12-31USD 3.2187.4%
20252025-12-31USD 3.6212.6%
Hikma Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-41.6%
Q22025-06-3081.4%
Q42025-12-31-30.8%
Q22026-06-3037.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.73B

+10.1%

Gross Profit

$727.86M

-3.7%

Gross Margin

42.13%

N/A

Market Cap

$4.60BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$488.91K

N/A

Employees

9,400

N/A

Net Income

$222.96M

-1.3%

EBITDA

$481.91M

+12.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$289.00M

+11.2%

Total Debt

$1.96B

+53.4%

Accounts Receivable

$1.12B

+19.6%

Inventory

$1.18B

+25.6%

Long Term Debt

$1.75B

+65.2%

Short Term Debt

$204.00M

-5.1%

Return on Assets

6.59%

N/A

Return on Invested Capital

14.83%

N/A

Free Cash Flow

$46.99M

-63.6%

Operating Cash Flow

$168.97M

-14.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
APNHYAspen Pharmacare Holdings Limited
$9.64+0.00%
AMRXAmneal Pharmaceuticals, Inc.
$19.18-0.36%
BHCBausch Health Companies Inc.
$6.30-0.16%
ANIPANI Pharmaceuticals, Inc.
$72.29+0.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$89.85-5.79%
NVDANvidia
$214.13-1.43%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$93.67-12.74%
CCCCCC Intelligent Solutions
$7.61-0.26%

Questions About HKMPY

What is the current price of Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc is trading at $44.41 per share.

What is the 52-week range for Hikma Pharmaceuticals Plc?

Over the past 52 weeks, Hikma Pharmaceuticals Plc has traded between $31.80 and $49.31.

How much debt does Hikma Pharmaceuticals Plc have?

As of the most recent reporting period, Hikma Pharmaceuticals Plc reported total debt of $1.60B.

How much cash does Hikma Pharmaceuticals Plc have on hand?

Hikma Pharmaceuticals Plc reported $328.00M in cash and cash equivalents in its most recent financial results.

What is Hikma Pharmaceuticals Plc’s dividend yield?

Hikma Pharmaceuticals Plc currently has a dividend yield of 3.87%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services